Morgan Stanley Downgrades Immuneering to Underweight From Equalweight, Removes $4 Price Target, Sets Base Case Range of $1-$5

摩根士丹利將Immuneering評級從持平下調至減持，移除4美元的目標價，設置基準區間爲1美元至5美元。

MT Newswires · 2024/12/13 03:50 · 評級/大行評級

Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.

登入免費觀看全文

登入/註冊

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。更多信息

Morgan Stanley Downgrades Immuneering to Underweight From Equalweight, Removes $4 Price Target, Sets Base Case Range of $1-$5

Morgan Stanley Downgrades Immuneering to Underweight From Equalweight, Removes $4 Price Target, Sets Base Case Range of $1-$5

熱門市場機會

熱門討論

熱門討論

Morgan Stanley Downgrades Immuneering to Underweight From Equalweight, Removes $4 Price Target, Sets Base Case Range of $1-$5

Morgan Stanley Downgrades Immuneering to Underweight From Equalweight, Removes $4 Price Target, Sets Base Case Range of $1-$5

風險及免責聲明

熱門市場機會

熱門討論

熱門討論

聲明